NCT04173065已完成2 期
VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 248
- 试验地点
- 79
- 主要终点
- Liver Fat
研究概览
简要总结
The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an equal distribution of males and females in each treatment arm. Subjects will be stratified by gender, fibrosis stage, and diabetes status.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and is willing and able to participate;
- •Have a histologically-confirmed diagnosis of NASH on a liver biopsy performed during screening or within 6 months before screening; for this study, confirmation requires:
- •NASH Clinical Research Network (CRN) fibrosis stage 1 to stage 3 and
- •NASH activity score (NAS) of ≥4 with at least a score of 1 in each of the following NAS components: ballooning degeneration (score = 0-2), lobular inflammation (score = 0-3) and steatosis (score = 0-3); (c) F1 subjects must have at least one of these risk factors: type 2 diabetes, body mass index of ≥ 30 mg/ m2, and/ or alanine aminotransferase > 1.5 x ULN
- •Have a screening MRI-PDFF with ≥ 8% liver fat fraction;
- •Male and females be 18 to 75 years of age, inclusive, at screening;
排除标准
- •Are unwilling to undergo the required liver biopsy procedures or have any condition that would prevent obtaining a liver biopsy as part of this clinical protocol
- •Have evidence of current or history of excessive alcohol consumption of more than 20 g per day for women and 30 g per day for men, on average, within 6 months before the qualifying liver biopsy and up to randomization, or are unable to provide a reliable estimate of alcohol consumption during this period;
- •Treatment with medications for the purpose of weight loss within 6 months prior to qualifying liver biopsy, unless approved after consultation with the medical monitor. These include drugs approved for weight loss (e.g. orlistat, bupropion/naltrexone, phentermine-topiramate, phentermine, lorcaserin), as well as drugs used off-label, herbal preparations and dietary supplements marketed for control of body weight or appetite;
- •TSH outside central laboratory reference range;
- •Free T4 outside central laboratory reference range;
- •Cardiac troponin I (cTnI) and creatine kinase MB isoenzyme (CK-MB) > Upper Limit of Normal (ULN) at screening;
- •Serum albumin < 3.5 g/dL;
- •International normalized ratio (INR) > 1.3;
- •Total bilirubin > 1.2 X ULN (except in presence of Gilbert synd
- •Strong or moderate inhibitors or inducers of CYP3A4 are prohibited during the study period
- •Drugs that may affect liver fat content or are associated with nonalcoholic fatty liver disease (NAFLD) are prohibited during the 3 month period prior to the baseline liver biopsy and up to the end of treatment
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebos (Drug)
1.0 mg
Experimental
干预措施: VK2809 (Drug)
2.5mg
Experimental
干预措施: VK2809 (Drug)
5.0 mg
Experimental
干预措施: VK2809 (Drug)
10 mg
Experimental
干预措施: VK2809 (Drug)
结局指标
主要结局
Liver Fat
时间窗: 12 weeks
Relative change in liver fat content (assessed by MRI-PDFF) from baseline to Week 12 in subjects treated with VK2809 compared to the change in subjects treated with placebo.
次要结局
- NASH CRN fibrosis score(52 weeks)
研究者
研究点 (79)
Loading locations...
相似试验
进行中（未招募）
1 期
A randomized, group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powder inhaler, versus placebo, in participants with asthma.MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-002843-40-PLGlaxoSmithKline Research & Development Ltd384
进行中（未招募）
1 期
BI 655066 proof of concept dose finding study in ASMedDRA version: 18.1Level: LLTClassification code 10002557Term: Ankylosing spondylitis and other inflammatory spondylopathiesSystem Organ Class: 100000004859Ankylosing SpondylitisEUCTR2013-003666-13-DEBoehringer Ingelheim Pharma GmbH & Co. KG212
进行中（未招募）
1 期
BI 655066 proof of concept dose finding study in ASAnkylosing SpondylitisEUCTR2013-003666-13-BESCS Boehringer Ingelheim Comm.V212
进行中（未招募）
1 期
BI 655066 proof of concept dose finding study in ASAnkylosing SpondylitisEUCTR2013-003666-13-FIBoehringer Ingelheim Finland Ky212
已完成
2 期
A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis.NL-OMON40442Boehringer Ingelheim10